Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 398-405

  Coleman, R ^a   De Boer, R ^b   Eidtmann, H ^c   Llombart, A ^d   Davidson, N ^e   Neven, P ^f   Von Minckwitz, G ^g   Sleeboom, H P ^h   Forbes, J ⁱ   Barrios, C ^j   Frassoldati, A ^k   Campbell, I ^l   Paija, O ^m   Martin, N ⁿ   Modi, A ⁿ   Bundred, N ^o  

^a Academic Unit of Clinical Oncology   (United Kingdom)

^b Royal Melbourne and Western Hospitals ^*  (Australia)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Medical Oncology Service   (Spain)

^e BROOMFIELD HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g German Breast Group   (Germany)

^h HAGA HOSPITAL   (Netherlands)

ⁱ UNIVERSITY OF NEWCASTLE   (Australia)

^j PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^k UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^l WAIKATO HOSPITAL   (New Zealand)

^m TURKU UNIVERSITY HOSPITAL   (Finland)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

^o MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Anticancer; Aromatase inhibitor; Bone loss; Breast cancer; Survival; Zoledronic acid

Indexed keywords

LETROZOLE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; FOLLOW UP; FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; THERAPY DELAY; TREATMENT DURATION;

EID: 84873825231     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds277     Document Type: Article

References (23)

1. Aebi S, Davidson T, Gruber G et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v9-v14.
2. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-3796.
3. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570.
4. Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141.
5. Goss PE, Ingle JN, Pater JL et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008; 26: 1948-1955.
6. Bundred NJ, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008; 112: 1001-1010.
7. Bainbridge KE, Sowers MF, Crutchfield M et al. Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am J Epidemiol 2002; 156: 410-417.
8. Ohta H, Makita K, Komukai S et al. Bone resorption versus estrogen loss following oophorectomy and menopause. Maturitas 2002; 43: 27-33.
9. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26: 1051-1057.
10. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9: 840-849.
11. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296: 235-242.
12. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 420446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-751.
13. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
14. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozoleinduced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829-836.
15. Llombart A, Frassoldati A, Paija O et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. In ASCO 2009 Breast Cancer Symposium (Abstr 213). San Francisco, CA, 2009.
16. Shapiro CL, Halabi S, Hars V et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47: 683-689.
17. Green JR, Guenther A. The backbone of progress-preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 2011; 77(Suppl 1): S3-S12.
18. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol 2010; 37(Suppl 1): S53-S65.
19. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
20. Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010; 21: 2188-2194.
21. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
22. Brufsky AM, Harker WG, Beck JT et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118: 1192-1201.
23. Coleman R, Bundred N, de Boer R et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. In 32nd Annual San Antonio Breast Cancer Symposium (Abstr 4082). San Antonio, TX, 2009.